Access to anti-retroviral drugs, female in Guinea

Guinea: Access to anti-retroviral drugs, female was 83.0% in 2024. ◆ Volatile

Latest (2024)
83.0%
Change on year
up 12.2%
World rank
53rd
of 141 countries
All-time high
83.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Guinea, 2000–2024

0204060802000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 1 %2005: 2 %2006: 5 %2007: 5 %2008: 9 %2009: 15 %2010: 19 %2011: 21 %2012: 29 %2013: 28 %2014: 33 %2015: 33 %2016: 37 %2017: 35 %2018: 40 %2019: 52 %2020: 57 %2021: 64 %2022: 73 %2023: 74 %2024: 83 %

Source: UNAIDS estimates. Measured in %.

Analysis

Guinea recorded 83.0% for access to anti-retroviral drugs, female in 2024. That is the highest value across all 25 years on record.

The figure is up 12.2% on the previous year and up 151.5% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Guinea peaked at 83.0% in 2024 and was at its lowest, 0.0%, in 2000.

Guinea ranks 53rd of 141 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Guinea, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Guinea, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 1.0%
2005 2.0% +100.0%
2006 5.0% +150.0%
2007 5.0% +0.0%
2008 9.0% +80.0%
2009 15.0% +66.7%
2010 19.0% +26.7%
2011 21.0% +10.5%
2012 29.0% +38.1%
2013 28.0% -3.4%
2014 33.0% +17.9%
2015 33.0% +0.0%
2016 37.0% +12.1%
2017 35.0% -5.4%
2018 40.0% +14.3%
2019 52.0% +30.0%
2020 57.0% +9.6%
2021 64.0% +12.3%
2022 73.0% +14.1%
2023 74.0% +1.4%
2024 83.0% +12.2%

Averages by decade

DecadeAverage LowestHighest Years
2000s 3.7% 0.0% 15.0% 10
2010s 32.7% 19.0% 52.0% 10
2020s 70.2% 57.0% 83.0% 5

Countries ranked near Guinea

  1. 50 Côte d'Ivoire 84.0% compare
  2. 50 Singapore 84.0% compare
  3. 50 South Africa 84.0% compare
  4. 53 Nepal 83.0% compare
  5. 53 Slovenia 83.0% compare
  6. 56 Portugal 82.0% compare

See the full ranking of 160 places →

More gender data for Guinea

All data for Guinea →

Frequently asked questions

What is access to anti-retroviral drugs, female in Guinea?
Access to anti-retroviral drugs, female in Guinea was 83.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Guinea?
The highest recorded value was 83.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Guinea?
The lowest recorded value was 0.0% in 2000.
How does Guinea rank for access to anti-retroviral drugs, female?
Guinea ranks 53rd out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Guinea?
Over the last ten years it is up 151.5%. The long-run trend across the full record is volatile.
Where does this Guinea data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Guinea. Statizoid, drawing on UNAIDS estimates. Retrieved 08 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/guinea/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/guinea/">Access to anti-retroviral drugs, female in Guinea</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.